EGFR and HER2 Expression in Primary Ovarian High-Grade Serous Carcinoma and Their Prognostic Value | ||
| Research in Oncology | ||
| Article 2, Volume 17, Issue 1, June 2021, Pages 9-16 PDF (523.83 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/resoncol.2020.43021.1115 | ||
| Authors | ||
| Mayada S. Farrag* 1; Ziad Emarah2; Waleed Elrefaie3; Nesrine S. Farrag4; Mohamed T. Hafez5; Khaled Abdelwahab5 | ||
| 1Department of Pathology, Faculty of Medicine, Port Said University, Port Said, Egypt | ||
| 2Medical Oncology Unit, Internal Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt | ||
| 3Department of Obstetrics and Gynecology, Faculty of Medicine, Port Said University, Port Said, Egypt | ||
| 4Department of Community Medicine and Public Health, Faculty of Medicine, Mansoura University, Mansoura, Egypt | ||
| 5Department of Surgical Oncology, Mansoura Oncology Center, Mansoura University, Mansoura, Egypt | ||
| Abstract | ||
| Background: Human epidermal growth factors receptors such as EGFR and HER2 play an important role in tumorigenesis and are used as therapeutic targets. Their role in aggressive primary ovarian high-grade serous carcinoma (HGSC) is controversial. Aim: To study the expression of EGFR and HER2 in ovarian HGSC, to correlate their expression with other clinicopathological parameters and to study their prognostic value. Methods: Imunohistochemical staining of EGFR, HER2 and Ki-67 was done for 54 ovarian HGSC specimens. According to the used scoring methods, the expression of EGFR and HER2 was classified as high or low. Results: High expression of EGFR and HER2 was found in a minority of specimens; 39% and 15%, respectively. None of the studied clinicopathological parameters correlated significantly with the expression of EGFR and HER2, except for the carcinoembryonic antigen level which correlated positively with HER2 expression. Disease-free survival of patients did not differ significantly according to the level of expression of EGFR and HER2 (p =0.684 and 0.186, respectively). Similarly, overall survival did not differ significantly (p =0.911 and 0.346, respectively). Conclusion: The results of this study suggest that the prognostic value of EGFR and HER2 in ovarian HGSC is questionable. | ||
| Keywords | ||
| EGFR; HER2; High-grade; Ovarian; Serous Carcinoma | ||
|
Statistics Article View: 653 PDF Download: 3,617 |
||
